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Abstract: Gaucher disease is a progressive lysosomal storage disorder caused by the deﬁ  ciency 
of glucocerebrosidase, and characterized by intralysosomal storage of glucosylceramide that leads 
to dysfunction in multiple organ systems. Intravenous enzyme replacement with imiglucerase is 
the accepted standard for treatment of symptomatic patients and has been effective in reducing 
many of the signs and symptoms of type I Gaucher disease in the majority of patients without 
serious adverse effects. An alternative therapeutic approach is substrate reduction therapy with 
N-butyldeoxynojirimycin (NB-DNJ) (miglustat; Zavesca®), an imino sugar that reversibly inhib-
its glucosylceremide synthase and reduces intracellular storage of glucosylceramide. Miglustat 
was recently approved in Europe and the United States for symptomatic patients with mild to 
moderate clinical manifestations for whom enzyme replacement therapy is not an option. This 
review article discusses the results of clinical studies and use of miglustat as a therapeutic agent 
in patients with type I Gaucher disease.
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First described by Dr. Philippe Gaucher in 1882, Gaucher disease is a lysosomal storage 
disorder that is caused by the deﬁ  ciency of glucocerebrosidase, and is characterized 
by the accumulation of glycosylceramide that leads to dysfunction in multiple organ 
systems (Beutler and Grabowski 1995). Three types of Gaucher disease have been 
described, but, actually, these represent different degrees of severity along a spectrum. 
The clinical features of type I Gaucher disease, the non-neuronopathic form, are sple-
nomegaly, which is more prominent than the hepatomegaly, anemia, thrombocytopenia, 
and bone lesions. Type II Gaucher disease is the most severe form, which presents with 
severe central nervous system involvement and is generally fatal within the ﬁ  rst 2 years 
of life. Type III Gaucher disease, the subacute neuronopathic form, presents in early 
childhood with severe manifestations resembling type I (splenomegaly, hepatomegaly, 
and bone lesions) and has a more chronic course with onset of neurological disease 
towards the end of the ﬁ  rst decade (Beutler and Grabowski 1995).
In 1991, the advent of targeted enzyme replacement therapy (ERT) using algucerase 
(Ceredase®; Genzyme Corporation) followed by the introduction of imiglucerase (Cer-
ezyme®; Genzyme Corporation) resulted in huge improvements in the treatment of 
patients with Gaucher disease. Imiglucerase is a modiﬁ  ed form of glucocerebrosidase, 
created using recombinant DNA technology, and is given as intravenous infusions, 
usually every other week. Imiglucerase acts like the naturally occurring enzyme glu-
cocerebrosidase to break down the glucosylceramide that has accumulated in Gaucher 
cells (Barton et al 1991; Grabowski et al 1998). In the majority of patients ( 90%), 
ERT has been effective in reducing many of the signs and symptoms of type I Gaucher 
disease but has no or limited effect on the neurologic ﬁ  ndings of type II and III Gaucher 
disease because of its inability to cross the blood – brain barrier (Weinreb et al 2002). Therapeutics and Clinical Risk Management 2008:4(2) 426
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Side effects (hypersensitivity reactions and neutralizing 
antibodies) related to ERT have been reported in less than 
15% of type I Gaucher patients (Barton et al 1991; Grabowski 
et al 1998). Life-long intravenous infusion every 2 weeks can 
be a burden for some patients, particularly in those with poor 
venous access. The high cost of ERT also precludes its use 
in some countries and burdens health care cost.
One of the key issues that researchers and pharmaceuti-
cal companies are still facing in the treatment of lysosomal 
disorders including Gaucher disease is the need to develop 
cheaper new treatments that will decrease the cost, provide 
easy administration of the drug, and improve and prevent 
neurological disease. Chemical chaperone therapy and gene 
therapy hold great promise as future treatment options for 
all three types of Gaucher disease.
An oral treatment using a small molecule (substrate reduc-
tion therapy) is an available form of therapy for type I Gaucher 
disease (Platt et al 2001). In 2002, N-butyldeoxynojirimycin 
(NB-DNJ) (miglustat; Zavesca®, Actelion Pharmaceuticals), 
a substrate reduction agent, was approved by EPAR and FDA 
as a treatment option for type I Gaucher disease (EPAR 2002; 
US FDA 2003).
Unlike ERT, miglustat is a small molecule and can pass 
the blood – brain barrier and has the potential to be effec-
tive in treating lysosomal storage disorders with neurologic 
manifestations. Capablo et al (2007) recently reported that 
combined imiglucerase and miglustat therapy improved 
some neurological manifestations of type III Gaucher in an 
adult patient. Miglustat has also been proposed for treat-
ment of other lysosomal diseases like Niemann Pick type C, 
Tay-Sachs, and Fabry disease (Abe et al 2000; Andersson 
et al 2004; Hear et al 2007; Patterson et al 2007). Miglustat 
therapy has been unsuccessful in halting the progress of 
infantile-onset Tay-Sachs disease (Bembi et al 2006). Pat-
terson et al (2007) showed that miglustat improved some neu-
rologic symptoms of patients with Nieman Pick type C.
How effective is miglustat as an alternative treatment to 
ERT for type I Gaucher disease? The present review assesses 
published clinical studies of miglustat as a therapeutic agent 
in patients with type I Gaucher disease.
Miglustat: substrate reduction 
therapy
Substrate reduction therapy is an alternative approach to treat 
patients with Gaucher disease. NB-DNJ (miglustat) is one 
of the N-alkylated iminosugars extracted from plants and 
microorganisms, and inhibits glycosylceramide synthase, 
which catalyzes the transfer of glucose from UDP-glucose 
to ceramide to form glucosylceramide (GlcCer) (Figure 1). 
The aim is to decrease the biosynthesis of GlcCer so that 
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Figure 1 Inhibition of glucosylceramide synthesis with miglustat.Therapeutics and Clinical Risk Management 2008:4(2) 427
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patients with signiﬁ  cant residual enzyme activity can break 
down GlcCer more efﬁ  ciently and thus allow clearance of 
GlcCer from lysosomes (Platt et al 2007).
Imino sugars such as NB-DNJ can also target the protein 
folding and trafﬁ  cking pathways of glycosidase to assist 
correction of lysosomal enzyme activity (Yam et al 2005) 
(chaperone mediated therapy). A partial increase in enzyme 
activity may be sufﬁ  cient to initiate the metabolic break-
down of glycosphyngolipids (GSL) and decrease the GSL 
storage in lysosomes. The efﬁ  cacy of miglustat in Gaucher 
disease type I probably results from both a decrease in the 
biosynthesis of GlcCer and an increase in the activity of 
glucocerebrosidase.
Discovery and development
of miglustat
In the 1990s Norman Radin hypothesized that it would be 
possible to reduce the concentration of glycosphingolipids 
substrates in the lysosomes by inhibiting their biosynthesis 
(Radin 1996, 2000; Platt et al 2001). Radin and colleagues 
synthesized compounds such as 1-phenyl-2-decanoyl-
amino-3-morpholino-1-propanol (PDMP) to inhibit GlcCer 
synthase, which is a key enzyme in GlcCer biosynthesis. 
More recently, several homologues of PDMP have been 
characterized (Abe et al 1992, 2001). However, PDMP and 
related compounds can inhibit cell growth, and cause unde-
sirable cell death (Barbour et al 1992; Abe et al 1995). In 
light of PDMP’s undesirable effects, compounds related to 
PDMP that do not exhibit these effects were chosen and used 
in several studies (Abe et al 1992). Several animal studies 
also showed that depletion of GSL could be lethal or lead 
to neurological disturbance, and substrate reduction therapy 
should be aimed to reduce biosynthesis of GSL to a degree 
that can be tolerated by cells (Radin 1996).
NB-DNJ, a compound originally developed as an 
alpha-glucosidase inhibitor and structurally unrelated to 
PDMP, is an N-alkylated imino sugar and is an inhibitor of 
GlcCer synthase. NB-DNJ was initially developed for use as 
an antiviral agent, because most enveloped viruses use the 
same pathway for glycoprotein synthesis in infected cells. 
Using NB-DNJ to alter the glycosylation of envelope glyco-
proteins could decrease the infectivity in certain viral diseases 
such as HIV. However, clinical trials on HIV patients were 
unsuccessful because the antiviral concentrations of NB-DNJ 
required could not be achieved in humans without a high 
incidence of adverse effects (Tierney et al 1995). These clini-
cal trials provided valuable safety information that helped to 
guide subsequent studies for SRT in Gaucher disease.
Results of clinical trials of miglustat 
in patients with type-I Gaucher 
disease
The current clinical experience with miglustat on type I 
Gaucher disease is based on the clinical studies undertaken 
since 2000.
In April 2000, Cox et al (2000) reported the results of 
the ﬁ  rst clinical trial, a 1-year open label uncontrolled study. 
Twenty-eight adults with type I Gaucher disease were treated 
with 100 mg oral miglustat 3 times a day for 12 months (Cox 
et al 2000). Twenty-two patients completed the study. Spleen 
and liver volumes were lowered by 19% (p   0.001) and 
12% (p   0.001), respectively, over 12 months (Table 1). 
Hematological markers such as hemoglobin and platelets 
improved slightly. Chitotriosidase levels fell by 16.4% 
(p   0.001) over 12 months (Table 1). The most frequent 
adverse effect was diarrhea, which occurred in 79% of 
patients. Two patients were withdrawn from the trial due 
to peripheral neuropathy, which was reported as an adverse 
Table 1 Changes in clinical parameters in response to miglustat treatment in clinical studies
  Cox et al 2000  Heitner et al 2002  Elstein et al 2002a Pastores  Giraldo
  Elstein et al 2004      et al 2005  et alb
  Initial   Extension  Initial  Extension    Initial study    24  Treatment
  study  study  study  study    6 mo      naïve group
  12 mo  36 mo  6 mo  12 mo          6 mo
Number of  22  14  17  16  Miglustat  ERT  Combination  7  10
subjects
Liver volume %  −12  −17.5  −5.9  −6.2  −2.9 3.6 −4.9  −5.6  −0.22 cm
Spleen volume %  −19  −29.6  −4.9  −10.1  −4.8  −2.1  −6.5  −15.4  −9.2 cm
Hemoglobin %  +0.26  +12.9  −1.3  +1.2  −0.31 g DL−1  −0.15 g DL−1  −0.10 g DL−1  −1.6  0.77 g DL−1
Platelets %  +8.3  +34.3  +2.0  +14.7  −21.6 × 109 l−1 15.3  × 109 l−1 2.7  × 109 l−1  +23 41.5  × 109 l−1
Chitothriosidase %  −16.4  −21.9 (24 mo)  −4.6  −15.3 33  −0.03  −3.9  −25.3  −38.2
aHemoglobin and platelets values are in g DL−1 and x109 l−1.
bLiver and spleen volumes are in cm; hemoglobin and platelets values are in g DL−1 and x109 l−1.Therapeutics and Clinical Risk Management 2008:4(2) 428
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effect of miglustat. Based on these results, the EPAR and US 
FDA approved miglustat (Zavesca®) for adult patients with 
mild-moderate type I Gaucher disease for whom enzyme 
replacement therapy is not an option.
Eighteen patients who completed the initial 12-month 
clinical trial were enrolled in an extension study; 14 com-
pleted the 24-month extension study. Elstein et al (2004) 
reported the results of the extension study in 2004. Liver and 
spleen volumes diminished by 18% and 30%, respectively 
(Table 1). Hemoglobin and platelets counts increased. No new 
cases of peripheral neuropathy were reported. Diarrhea and 
weight loss decreased in magnitude and prevalence during the 
second and third years. This trial suggests that adverse effects 
diminished when the period of treatment was extended.
In 2002, Heitner et al (2002) reported the result of a 
6-month open label uncontrolled study in which 18 adult 
patients with type I Gaucher received low dose miglustat 
(50 mg 3 times a day). Seventeen patients completed the 
6-month study which reported the signiﬁ  cant mean percent-
age changes in liver (–5.9%) and spleen (–4.5%) volumes 
and in chitotriosidase levels (–4.6%) (Table 1). The lower 
dose of miglustat (50 mg 3 times a day) did not produce the 
same beneﬁ  cial effects delivered by the higher dose (100 mg 
3 times a day) while patients suffered similar adverse effects 
(diarrhea and weight loss)
Sixteen patients were enrolled in a 6-month extension to 
this study. After a total of 12 months’ treatment, spleen and 
liver volumes, and chitotriosidase levels decreased by only 
10%, 6%, and 15%, respectively (Table 1). There were no sig-
niﬁ  cant changes in hemoglobin levels or platelets counts.
The third study was undertaken by Elstein et al (2002). 
It was an open label, controlled, 6-month trial to assess the 
efﬁ  cacy of miglustat as a maintenance therapy. Thirty-six 
patients who had received ERT for a minimum 2 years were 
enrolled in the study and randomized into one of three groups: 
ERT monotherapy, miglustat monotherapy (100 mg 3 times a 
day) and ERT and miglustat combined therapy. Thirty-three 
patients completed the study. No signiﬁ  cant differences were 
noted among the three groups in terms of changes in liver 
and spleen volumes and hemoglobin levels after 6 months 
of treatment (Table 1). The miglustat monotherapy group 
had a 33% increase in mean chitotriosidase level compared 
with both ERT and combined treatment groups, both of 
which recorded desired stable or decreased levels (Table 1). 
The miglustat monotherapy group showed a mean absolute 
decrease in platelet count (–21.6 × 109/L) while the other 
two groups showed some absolute increase in platelet counts 
(Table 1). Twenty-nine patients were enrolled in a 6-month 
extension to this study. ERT was discontinued and all patients 
received only miglustat 100 mg 3 times a day. There were no 
signiﬁ  cant changes in liver, spleen volume, or hemoglobin 
level. Mean platelet counts decreased and chitotriosidase level 
increased. The authors suggested that miglustat monotherapy 
might not be sufﬁ  cient to maintain the same control of disease 
in all patients (Elstein et al 2002; Zimran and Elstein 2003).
In 2005, Pastores et al (2005) undertook a 2-year open 
label study and enrolled 10 adults who received 100 mg 
miglustat 3 times a day. Seven out of 10 patients com-
pleted the 2-year study. Chitotriosidase levels decreased by 
25.4% over 2 years (Table 1). At 18 months, spleen volume 
decreased by 24.3%, liver volume by 15.1%. Hematological 
parameters such as the platelet count improved over 2-year 
period. This study conﬁ  rmed the ﬁ  ndings of Elstein et al 
(2004) that adverse effects such as diarrhea, abdominal pain, 
distension, weight loss tremors, and paresthesia decrease over 
the course of the trial. It also produced similar beneﬁ  cial 
effects to those reported by Cox et al (2000).
In 2007, Elstein et al (2007) reported the results of a 
2-year open label trial in which 36 clinically stable patients 
on enzyme replacement therapy were enrolled and the effects 
of combined enzyme and miglustat therapy compared with 
miglustat monotherapy. This was an extension of the previ-
ously reported 6-month clinical trial, Elstein et al (2002).
Miglustat was well tolerated by both groups, and the safety 
proﬁ  le was consistent with the previous trials. They suggested 
that miglustat could be an effective maintenance therapy in 
stabilized patients with type 1 Gaucher.
Departing from previous clinical trials with their focus on 
hematologic markers, and liver and spleen volumes, Pastores 
et al (2007) evaluated the effects of miglustat on bone mani-
festations and bone mineral density. They recruited 72 patients 
with type I Gaucher disease, who had previously participated 
in 3 multinational, open-label clinical trials of miglustat. The 
data were collected prospectively over an observation period 
of 2 years. At study entry, osteoporosis (68%) and bone pain 
(63%) were the most common bone-related ﬁ  ndings. They 
showed that 83% of the patients reported no bone pain and 
BMD Z-scores were improved from baseline at both the 
lumbar spine and femoral neck at each time point (months 6, 
12, and 24). The authors suggested that the beneﬁ  cial effect of 
miglustat on bone symptoms might be explained by its wide 
tissue distribution and by a direct effect on bone cells.
In 2007, Giraldo et al (2006) reported the results of 
an open label 12-month study. Twenty-ﬁ  ve patients (10 
therapy naïve, 15 previously treated with ERT) with mild to 
moderate Gaucher disease type 1 were treated with miglustat.Therapeutics and Clinical Risk Management 2008:4(2) 429
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At 6 months, the previously untreated group showed a 
mean increase in hemoglobin of 0.77 g/dL, platelet count 
of 41.5 × 109/L or remained stable, and a mean decrease in 
their chitotriosidase levels of 38.2% (Table 1). Their results 
were similar to those treated with ERT only. They concluded 
that the efﬁ  cacy of miglustat therapy after 6 months was 
comparable to that of ERT.
Adverse reactions/safety/
precautions
Gastrointestinal symptoms
Diarrhea and weight loss were common in the clinical studies 
(13, 15, 18, 20, 23, 24). Diarrhea is probably due to inhibition 
of disaccharidase activity by miglustat in the intestine that 
results in osmotic diarrhea. Diarrhea was noted to improve 
over time whether or not the dose of miglustat was decreased. 
Some patients were treated with anti-diarrheal medications 
such as loperamide. The cause of weight loss is unknown. 
The incidence of weight loss was more common in the ﬁ  rst 
12 months of treatment and most of patients recovered from 
the weight loss by 24 months of treatment.
Neurological symptoms
Tremor was reported in about 30% of patients (Cox et al 2003). 
It was more common within the ﬁ  rst month of treatment and 
improved between 1 to 3 months during treatment and resolved 
spontaneously, or after reduction of dose or discontinuation of 
miglustat. Parasthesias and burning sensation due to periph-
eral neuropathy were reported in 15%–20% of patients, and 
resolved after the discontinuation of the medication or dose 
reduction (Cox et al 2000; Pastores et al 2005). Cognitive 
dysfunction was reported in 5 patients, but no causal rela-
tionship was found (Elstein et al 2005). Baseline and repeat 
neurological evaluations at about 6-month intervals are recom-
mended for all patients who will be treated with miglustat.
Reproduction toxicity/pregnancy/
breast feeding
Animal studies showed that miglustat adversely affects 
spermatogenesis and sperm parameters and reduces fertil-
ity (Walden et al 2006). In contrast to the observations in 
mice, the recently published study showed that miglustat 
has no apparent effect on spermatogenesis in man (Amory 
et al 2007).
Reproductive effects in females could be increased post-
implantation loss and early embryonic death, and dystocia. 
It is not clear if these toxic effects will be reversible after 
long-term treatment. Animal studies showed that miglustat 
could cause fetal harm when administered to a pregnant 
animal. Miglustat is contraindicated in women who are or 
may become pregnant. Male patients are recommended to 
use a contraceptive method while taking miglustat, and for 
3 months after its discontinuation.
It is unknown if miglustat is excreted in human milk. 
Because of potential serious adverse reactions of miglustat in 
nursing infants, it should not be used in nursing mothers.
Conclusion
Miglustat is an oral medication that inhibits glucosylceremide 
synthase (substrate reduction therapy) and may partially 
increase glucocerebrosidase enzyme activity (chaperone 
mediated therapy). Studies showed that miglustat did 
improve the biochemical outcomes of patients with mild to 
moderate type 1 Gaucher during clinical trials ranging from 
6 to 36 months, but there is insufﬁ  cient evidence to show if 
treatment will maintain both clinical and biochemical effects 
over a long-term period, or on its efﬁ  ciency in treating the 
bones and preventing serious aspects such as pulmonary 
hypertension.
Bone manifestations are considered among the most 
painful and debilitating components of type I Gaucher. 
ERT can improve the bone symptoms but it takes much 
longer to achieve satisfactory results (Charrow et al 2007). 
However, recently published data shows that miglustat may 
well improve bone density and prevent bone crisis (Pastores 
et al 2007). Long-term studies are needed to support this 
ﬁ  nding.
While some splenectomized patients participated in the 
clinical trials, no studies have yet evaluated the impact of 
splenectomy on the effectiveness of miglustat. Splenec-
tomy is thought to impact adversely the severity of bone 
disease.
Currently, miglustat has limited indication for use in 
only adults with mild, moderate type I Gaucher disease in 
the USA and Europe, due to lack of information about the 
beneﬁ  cial effects on severe cases (Cox et al 2003). Potential 
advantages of miglustat should be carefully weighed in indi-
vidual patients, and the treatment decision should be made by 
physicians with expertise in Gaucher disease. Patients with 
some residual enzyme activity and mild symptoms of type I 
Gaucher disease can be treated with miglustat if ERT is not 
an option. It is essential to monitor the disease progression 
by checking levels of hemoglobin, platelets, chitotriosidase 
every 3–6 months and liver and spleen volumes and bone 
studies including dual energy X-ray absorptiometry (DXA) 
scan and bone MRI once a year.Therapeutics and Clinical Risk Management 2008:4(2) 430
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The adverse effects such as weight loss, diarrhea, and 
tremors are dose related and reversible, but close neurologic 
follow up is recommended due to possible complications such 
as peripheral neuropathy and cognitive decline. None of the 
authors discussed how much the adverse effects interfered 
with the patients’ daily activities of living.
The potential long-term neurologic adverse effects of 
miglustat are difﬁ  cult to assess from available studies. There 
seems to be a direct association between using miglustat and 
developing tremors. The cause of peripheral neuropathy was 
attributed to vitamin B12 deﬁ  ciency in some patients but 
the use of miglustat was not totally excluded as a cause of 
peripheral neuropathy. Patients who were on miglustat did 
perform signiﬁ  cantly poorer than patients who were not on 
miglustat on tests measuring verbal learning and memory on 
psychologist administrated tests, but this difference between 
two groups was not observed in computer assessed tests 
(Elstein et al 2005). It is not clear if patients on miglustat are 
at greater risk for verbal and memory difﬁ  culties.
None of the studies addresses cardiac and pulmonary 
status especially regarding pulmonary hypertension, and 
quality of life.
Additional controlled longitudinal studies are needed to be 
undertaken with a larger number of patients not only to deter-
mine the biochemical but also clinical long term outcomes of 
patients with type I Gaucher disease on miglustat therapy.
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